This paper is only available as a PDF. To read, Please Download here.
Abstract
The CONSORT dosing algorithm individualizes recombinant human FSH (r-hFSH) doses for assisted reproduction technologies, assigning 37.5 IU increments according to patient characteristics: basal FSH, body mass index, age and antral follicle count. A prospective, uncontrolled, international, 18-centre, pilot study of normo-ovulatory women aged 18–34 years inclusive undergoing a long agonist treatment protocol was performed. Follitropin alfa filled-by-mass (GONAL-f®) dose was assigned by the algorithm and was intended to be altered only for risk of ovarian hyperstimulation syndrome (OHSS). Primary end-point was number of oocytes retrieved. Dose groups containing ≥5 patients were analysed: 75 IU (n = 48), 112.5 IU (n = 45), 150 IU (n = 34), 187.5 IU (n = 24), 225 IU (n = 10). Cancellations due to inadequate response were higher than expected in the 75 IU group (12/48). Overall, a median of 9.0 oocytes were retrieved (8.5, 8.0, 10.0, 12.0 and 8.0 in the 75, 112.5, 150, 187.5 and 225 IU groups respectively). Clinical pregnancy rates/cycle started were 31.3, 31.1, 35.3, 50.0 and 20.0%, respectively (overall, 34.2%). Two patients had severe OHSS. Use of the CONSORT algorithm achieved an adequate oocyte yield and good pregnancy rates in this preliminary study. Adjustment of the algorithm could reduce cancellation rates.
Keywords
References
- Repeated testing of basal FSH levels has no predictive value for IVF outcome in women with elevated basal FSH.Human Reproduction. 2006; 21: 171-174
- Assisted reproductive technology in Europe, 2002. Results generated from European registers by ESHRE.Human Reproduction. 2006; 21: 1680-1697
- Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial.Human Reproduction. 2007; 22: 980-988
- A model for follicular selection and ovulation: lessons from superovulation.Journal of Steroid Biochemistry. 1987; 27: 15-23
- Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization.Fertility and Sterility. 2004; 81: 35-41
- Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis.Fertility and Sterility. 2003; 79: 1091-1100
- Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve.Fertility and Sterility. 2002; 77: 328-336
- Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH.Reproductive BioMedicine Online. 2005; 10: 169-177
- Evidence-based clinical outcome of oocyte slow cooling.Reproductive BioMedicine Online. 2007; 15: 175-181
- Cumulative pregnancy rates resulting from the use of fresh and frozen oocytes: 7 years' experience.Reproductive BioMedicine Online. 2006; 12: 481-486
- Clinical outcome of oocyte cryopreservation after slow cooling with a protocol utilizing a high sucrose concentration.Human Reproduction. 2006; 21: 512-517
- A systematic review of tests predicting ovarian reserve and IVF outcome.Human Reproduction Update. 2006; 12: 685-718
- Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.Human Reproduction Update. 2002; 8: 559-577
- Dynamics of FSH-induced follicular growth in subfertile women: relationship with age, insulin resistance, oocyte yield and anti-Mullerian hormone.Human Reproduction. 2006; 21: 1436-1441
- A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial.Lancet. 2007; 369: 743-749
- Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count.Fertility and Sterility. 2007; 87: 764-775
- A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.Journal of Clinical Endocrinology and Metabolism. 2003; 88: 166-173
- Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients.Current Medical Research and Opinion. 2006; 22: 907-918
- Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.Reproductive BioMedicine Online. 2004; 8: 635-643
- Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation.Human Reproduction. 2002; 17: 2016-2021
- Cryopreservation: the problem of evaluation.Human Reproduction. 1995; 10: 2136-2138
- Cryopreservation of supernumerary oocytes in IVF/ICSI cycles.Human Reproduction. 2006; 21: 370-375
- Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.Reproductive BioMedicine Online. 2004; 8: 175-182
- A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard’ dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment.Human Reproduction. 2003; 18: 2275-2282
- A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram.Human Reproduction. 2003; 18: 781-787
- Live-birth rates and multiple-birth risk using in vitro fertilization.JAMA: The Journal of the American Medical Association. 1999; 282: 1832-1838
- Factors that affect outcome of in-vitro fertilisation treatment.Lancet. 1996; 348: 1402-1406
- What is the most relevant standard of success in assisted reproduction? The value of cryopreservation on cumulative pregnancy rates per single oocyte retrieval should not be forgotten.Human Reproduction. 2004; 19: 2439-2441
- Common statistical errors in the design and analysis of subfertility trials.Human Reproduction. 2003; 18: 1000-1004
- Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo.Fertility and Sterility. 2001; 76: 962-968
- Optimum number of oocytes for a successful first IVF treatment cycle.Reproductive BioMedicine Online. 2006; 13: 476-480
- Delaying childbearing: effect of age on fecundity and outcome of pregnancy.British Medical Journal. 1991; 302: 1361-1365
- Predictors of low response to mild ovarian stimulation initiated on cycle day 5 for IVF.Human Reproduction. 2007; 22: 1919-1924
- Assisted reproductive technology surveillance – United States, 2001.MMWR Surveillance Summary. 2004; 53: 1-20
- Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories.Fertility and Sterility. 2005; 83: 24-29
Biography
Francois Olivennes attended medical school in Paris and then studied for his PhD in Biology of Reproduction at the University Pierre et Marie Curie in Paris. Following a fellowship under Pr Zev Rosenwaks in Cornell Medical College in New York, he returned to work in France. He was successively medical director of the french ART units in A. Beclere Hospital in Clamart with Rene Frydman and in Cochin Hospital in Paris. He is now coordinator of the private IVF centre of Eylau La Muette in Paris. He was a member of the ESHRE executive comittee from 2003 to 2007. His research interests include obstetric and peadiatric outcome of IVF, development of ovarian stimulation protocols and prevention of IVF complications.
Article info
Publication history
Accepted:
October 20,
2008
Received:
April 11,
2008
Footnotes
Trial registry number: NCT00249834 (ClinicalTrials.gov); 2004–000335–28 (EudraCT).
Declaration: This study was funded by Merck Serono S.A. (an affiliate of Merck Serono KGaA, Darmstadt, Germany), Geneva, Switzerland (Study 25198).
Identification
Copyright
© 2009 Reproductive Healthcare Ltd, Duck End Farm, Dry Drayton, Cambridge CB23 8DB, UK. Published by Elsevier Inc. All rights reserved.
